BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32363114)

  • 1. Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response.
    Song M; Wang C; Wang H; Zhang T; Li J; Benezra R; Chouchane L; Sun YH; Cui XG; Ma X
    Oncoimmunology; 2020; 9(1):1746148. PubMed ID: 32363114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
    Liao L; Song M; Li X; Tang L; Zhang T; Zhang L; Pan Y; Chouchane L; Ma X
    Cancer Res; 2017 Apr; 77(8):2090-2101. PubMed ID: 28330927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Yu Z; Dong X; Song M; Xu A; He Q; Li H; Ouyang W; Chouchane L; Ma X
    Int J Cancer; 2024 Feb; 154(4):723-737. PubMed ID: 37855385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
    Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
    Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
    [No Abstract]   [Full Text] [Related]  

  • 5. Modulation of myocardin function by the ubiquitin E3 ligase UBR5.
    Hu G; Wang X; Saunders DN; Henderson M; Russell AJ; Herring BP; Zhou J
    J Biol Chem; 2010 Apr; 285(16):11800-9. PubMed ID: 20167605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of UBR5 promotes tumor growth in gallbladder cancer via PTEN/PI3K/Akt signal pathway.
    Zhang Z; Zheng X; Li J; Duan J; Cui L; Yang L; Zhang L; Zhang Q; Wang X
    J Cell Biochem; 2019 Jul; 120(7):11517-11524. PubMed ID: 30775814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UBR5 regulates proliferation and radiosensitivity in human laryngeal carcinoma via the p38/MAPK signaling pathway.
    Wang K; Tang J; Liu X; Wang Y; Chen W; Zheng R
    Oncol Rep; 2020 Aug; 44(2):685-697. PubMed ID: 32468011
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Qiao X; Liu Y; Prada ML; Mohan AK; Gupta A; Jaiswal A; Sharma M; Merisaari J; Haikala HM; Talvinen K; Yetukuri L; Pylvänäinen JW; Klefström J; Kronqvist P; Meinander A; Aittokallio T; Hietakangas V; Eilers M; Westermarck J
    Cancer Res; 2020 Apr; 80(7):1414-1427. PubMed ID: 32029551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of phosphorylation sites on the E3 ubiquitin ligase UBR5/EDD.
    Bethard JR; Zheng H; Roberts L; Eblen ST
    J Proteomics; 2011 Dec; 75(2):603-9. PubMed ID: 21924388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of UBR5 in tumor proliferation and oncotherapy.
    Hu B; Chen S
    Gene; 2024 May; 906():148258. PubMed ID: 38331119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the human UBR5 E3 ubiquitin ligase.
    Wang F; He Q; Zhan W; Yu Z; Finkin-Groner E; Ma X; Lin G; Li H
    Structure; 2023 May; 31(5):541-552.e4. PubMed ID: 37040767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
    Matsuura K; Huang NJ; Cocce K; Zhang L; Kornbluth S
    Oncogene; 2017 Mar; 36(12):1698-1706. PubMed ID: 27721409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBR5 is a novel E3 ubiquitin ligase involved in skeletal muscle hypertrophy and recovery from atrophy.
    Seaborne RA; Hughes DC; Turner DC; Owens DJ; Baehr LM; Gorski P; Semenova EA; Borisov OV; Larin AK; Popov DV; Generozov EV; Sutherland H; Ahmetov II; Jarvis JC; Bodine SC; Sharples AP
    J Physiol; 2019 Jul; 597(14):3727-3749. PubMed ID: 31093990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.
    Xiang G; Wang S; Chen L; Song M; Song X; Wang H; Zhou P; Ma X; Yu J
    Cell Death Dis; 2022 May; 13(5):451. PubMed ID: 35551175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin.
    Yang Y; Zhao J; Mao Y; Lin G; Li F; Jiang Z
    Breast Cancer Res Treat; 2020 Dec; 184(3):699-710. PubMed ID: 32914356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia.
    Shearer RF; Frikstad KM; McKenna J; McCloy RA; Deng N; Burgess A; Stokke T; Patzke S; Saunders DN
    Mol Biol Cell; 2018 Jul; 29(13):1542-1554. PubMed ID: 29742019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen.
    Schukur L; Zimmermann T; Niewoehner O; Kerr G; Gleim S; Bauer-Probst B; Knapp B; Galli GG; Liang X; Mendiola A; Reece-Hoyes J; Rapti M; Barbosa I; Reschke M; Radimerski T; Thoma CR
    Sci Rep; 2020 Nov; 10(1):20044. PubMed ID: 33208877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1.
    Yang M; Jiang N; Cao QW; Ma MQ; Sun Q
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1624-9. PubMed ID: 27590582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review: targeting UBR5 domains to mediate emerging roles and mechanisms: chance or necessity?
    Wang Y; Niu K; Shi Y; Zhou F; Li X; Li Y; Chen T; Zhang Y
    Int J Surg; 2024 May; ():. PubMed ID: 38701508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBR5 inhibits the radiosensitivity of non-small cell lung cancer cells via the activation of the PI3K/AKT pathway.
    Gu YF; Ge XP
    J Investig Med; 2021 Jun; 69(5):970-975. PubMed ID: 33811132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.